Category: Oncology
June – A Month to Celebrate Cancer Survivorship
June is a month of commemoration and appreciation for the indomitable spirit of those who have triumphed over cancer. Cancer Survivor Month provides an opportunity…
Subcutaneous Rituximab Demonstrates Superior Outcomes Compared to Intravenous Administration in low–tumor burden follicular lymphoma – Phase III trial (FLIRT)
Subcutaneous Rituximab Demonstrates Superior Outcomes Compared to Intravenous Administration: Enhanced Complete Response Rates and Prolonged Progression-Free Survival – phase III trial (FLIRT) in low tumor…
Addition of Cabozantinib with immunotherapy Ipilimumab (IPI) and Nivolumab (NIVO) in previously untreated advanced clear-cell renal cell carcinoma (RCC) showed PFS benefit in intermediate risk group: COSMIC-313 trial
The COSMIC-313 trial is a phase III clinical trial that investigated the efficacy and safety of combining cabozantinib with the immunotherapy drugs ipilimumab (IPI) and…
MET Inhibitors: Promising Treatment Options for Non-Small Cell Lung Cancer
Capmatinib (Tabrecta) is a type of MET inhibitor that has shown promising results in the treatment of non-small cell lung cancer (NSCLC) that has a specific…
Patritumab deruxtecan or HER3-DXd: A novel antibody-drug conjugate in locally advanced or metastatic non-small cell lung cancer (NSCLC) with prior EGFR TKI therapy
Patritumab deruxtecan or HER3-DXd is a novel antibody-drug conjugate that consists of a HER3 antibody attached to a topoisomerase I inhibitor payload via a cleavable…
Neuroendocine Malignancies
Neuroendocrine malignancies, are a type of cancer that develops in cells of the neuroendocrine system. The neuroendocrine system is made up of cells that produce…
Localized Prostate Cancer Treatment Study in the UK: 15-Year Follow-Up Finds Low Prostate Cancer-Specific Mortality Regardless of Treatment Assigned
The localized prostate cancer treatment study published in the New England Journal of Medicine in April 2023, conducted in the United Kingdom from 1999 to…
Lunsumio (Mosunetuzumab-axgb): A New Hope for Relapsed or Refractory Follicular Lymphoma Patients
Mosunetuzumab-axgb: A New Hope for Relapsed or Refractory Follicular Lymphoma Patients Introduction: Follicular lymphoma (FL) is a type of non-Hodgkin’s lymphoma that arises from abnormal…
New Approval by FDA for Polatuzumab Vedotin-piiq with R-CHP for Previously Untreated DLBCL: Positive Results from POLARIX Trial
The Food and Drug Administration has granted approval in April 2023 to the use of polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) in combination with rituximab product,…
Frontline Treatment Options in Renal Cell Cancer
Renal cell cancer is a type of cancer that affects the kidneys, and treatment options for this condition depend on the stage of the cancer,…